Long-term efficacy and safety of oral almotriptan: Interim analysis of a 1-year open study

Headache

Volumn 41, Issue 1, 2001, Pages 57-62

  Cabarrocas, Xavier ^a   Esbri, Ramon ^a   Peris, Francesc ^a   Ferrer, Pau ^a  

^a Laboratories Almirall SA ^*  (Spain)

Author keywords

Almotriptan; Clinical trial; Interim report; Migraine attacks; Selective 5 HT1B 1D; Tolerability

Indexed keywords

ALMOTRIPTAN; SEROTONIN AGONIST;

ADULT; AGED; ARTICLE; BACKACHE; BRONCHITIS; CLINICAL TRIAL; DEPRESSION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NAUSEA; PAIN ASSESSMENT; PARESTHESIA; PRIORITY JOURNAL; SELF REPORT; THORAX PAIN; VERTIGO; VOMITING; XEROSTOMIA;

ADULT; AGED; FEMALE; HUMANS; INDOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 0035128857     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2001.111006057.x     Document Type: Article

References (7)

1. Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol Clin. 1997;15:1-13.
2. Welch KM. Pathogenesis of migraine. Semin Neurol. 1997;17:335-341.
3. Warshaw LJ, Lipton RB, Silberstein SD. Migraine: a "woman's disease?" Women Health. 1998;28:79-99.
4. Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs. 1998;56:811-824.
5. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
6. Skaer TL. Clinical presentation and treatment of migraine. Clin Ther. 1996;18:229-245.
7. Karch FE, Lasagna L. Adverse drug reactions. A critical review. JAMA. 1975;234:1236-1241.